Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Small molecule calcineurin inhibition
What ifWhat if a topical ointment used a small-molecule calcineurin inhibitor as its active ingredient?
Claim language“extracellular vesicle (EV) as an active ingredient”
An ointment base distributes the inhibitor across affected skin. In T cells, the inhibitor binds an intracellular binding protein, and the resulting complex inhibits calcineurin and reduces transcription of inflammatory cytokines.
1.1Antibody blockade of cytokine signaling
What ifWhat if an injected monoclonal antibody blocked cytokine signaling through a shared receptor subunit?
Claim language“extracellular vesicle (EV) as an active ingredient”
A buffered aqueous injection delivers an antibody against the alpha subunit of the interleukin-4 receptor. Antibody binding inhibits signaling by interleukin-4 and interleukin-13, reducing type 2 inflammation.
1.1Topical phosphodiesterase inhibition
What ifWhat if a topical ointment used a small-molecule phosphodiesterase-4 inhibitor as its active ingredient?
Claim language“extracellular vesicle (EV) as an active ingredient”
The ointment delivers the inhibitor to affected skin. Inhibition of phosphodiesterase-4 slows cyclic AMP breakdown in inflammatory cells and reduces the release of inflammatory mediators.
1.1Topical glucocorticoid receptor activation
What ifWhat if a topical cream used a corticosteroid to suppress inflammation in affected skin?
Claim language“extracellular vesicle (EV) as an active ingredient”
An oil-in-water cream distributes the corticosteroid over lesions. The corticosteroid enters skin cells and binds the glucocorticoid receptor, changing gene expression and reducing production of inflammatory mediators.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Component substitution
Topical gel with synthetic liposomes
Synthetic phosphatidylcholine and cholesterol liposomes carrying niacinamide replace the sea cucumber extracellular vesicles in a topical formulation. The liposomes form when an aqueous niacinamide solution hydrates a dry lipid film, and size-exclusion chromatography separates the liposomes from unencapsulated niacinamide. A hydroxyethylcellulose gel holds the liposome dispersion against the application surface.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1a Stichopus japonicus-derived extracellular vesicle (EV) as an active ingredient.
For example, the disclosed extracellular vesicles may be used for delivering a therapeutic agent such as cargo RNA to a target cell, where the methods include contacting the target cell with the disclosed extracellular vesicles.
A · US 2017/0087087 A1 · ¶ 49
In one aspect, the present disclosure provides a method of treating (including preventing) pulmonary hypertension, comprising administering to a subject in need thereof isolated extracellular vesicles or exosomes obtained from mesenchymal stromal cells, wherein the isolated extracellular vesicles or exosomes comprise extracellular vesicles or exosomes having increased expression of one or more expression products selected from the group consisting of (a) genes in the glycolys
B · US 2018/0296606 A1 · ¶ 5
An empty cell means only that no passage was reproduced there.
Statements in these documents
This method is novel in that it is the first to acknowledge and address the widespread problem of cleavage of targeting ligands from the luminal terminus extra of integral exosome membrane proteins during exosome biogenesis.
A · US 2017/0087087 A1 · ¶ 4
This targeting system can be used for engineering exosomes as targeted gene therapy or drug delivery vehicles in vivo, which could be applied to a wide variety of cell types and diseases.
A · US 2017/0087087 A1 · ¶ 4
The present application relates to methods of isolating potent extracellular vesicles, including exosomes, and the use of extracellular vesicles or exosomes in treatment of pulmonary hypertension, including pulmonary arterial hypertension (PAH), and conditions and diseases associated with mitochondrial dysfunction.
B · US 2018/0296606 A1 · ¶ 2
Thus, a need exists to develop improved therapeutic compositions and methods for treating pulmonary hypertension, such as by targeting mitochondrial function.
B · US 2018/0296606 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0355259 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355259/, SHA-256 e4cd1598e9fc1ed69454e88c490e66a7645feac4230492c7c0e49c08d0a93287